13:02 EST Edgewise, Caribou higher after WSJ report of Cytokinetics buyout
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EWTX:
- Edgewise shares still reflect limited credit for EDG-7500, says Wedbush
- Edgewise Therapeutics rises after Cytokinetics succeeds in HCM trial
- Oppenheimer, Wedbush say buy these biotech stocks for 2024
- FDA grants Edgewise ODD, RPDD for EDG-5506 to treat Duchenne, Becker MD
- Edgewise Duchenne and Becker Muscular Dystrophy treatment granted orphan status
